BANK VONTOBEL/CALL/MEDTRONIC/82/0.1/20.12.24 Stock

Warrant

DE000VD3SVN4

Market Closed - Boerse Frankfurt Warrants 14:02:39 2024-07-05 EDT
0.26 EUR +8.33% Intraday chart for BANK VONTOBEL/CALL/MEDTRONIC/82/0.1/20.12.24
Current month-18.75%
1 month-46.94%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.26 +8.33%
24-07-04 0.24 -4.00%
24-07-03 0.25 +4.17%
24-07-02 0.24 -4.00%
24-07-01 0.25 -21.88%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 02:02 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Vontobel Vontobel
WKN VD3SVN
ISINDE000VD3SVN4
Date issued 2024-04-09
Strike 82 $
Maturity 2024-12-20 (166 Days)
Parity 10 : 1
Emission price 0.71
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.82
Lowest since issue 0.234
Spread 0.01
Spread %3.70%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.61 USD
Average target price
94.02 USD
Spread / Average Target
+21.15%
Consensus